William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating on April 6.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sami Corwin has given his Buy rating due to a combination of factors related to rese-cel’s emerging profile in autoimmune diseases and the strength of recent RESET-MG data. The new results show a favorable safety picture with only limited cytokine release events, no ICANS, and robust B-cell depletion that is translating into clinically meaningful functional gains for most treated myasthenia gravis patients.
At the same time, management is pursuing a differentiated development path that includes preconditioning-free regimens and remains on schedule to outline pivotal trial designs in systemic sclerosis and myasthenia gravis. Additional upcoming readouts, such as full datasets from RESET-SLE and RESET-SSc along with initial Cell Shuttle manufacturing data, provide multiple catalysts that could further validate rese-cel’s strategy and support upside to Cabaletta Bio’s valuation.
In another report released on April 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.